Announcement
13 Jun 2024
In June 2024, US BARDA awarded USD 453 million to Vaxart Inc to support the planning and execution of a Phase 2b clinical trial for their oral COVID-19 vaccine candidate.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
13 Jun 2024
Revocation date:
No revocation date
Updated: 13 Jun 2024
State aid, unspecified
In force
On 13 June 2024, the Biomedical Advanced Research and Development Authority (BARDA) awarded USD 453 million to Vaxart Inc to support the planning and execution of a Phase 2b clinical trial for thei...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.